• European Patent Office issued intention to grant midkine antibody patent which covers one of the lead drugs in Cellmid’s midkine program
• This patent provides comprehensive protection over midkine antibodies in several disease settings including cancer, inflammatory diseases and autoimmune conditions
• Important milestone in clinical development program for midkine assets
• Significant value-add to the midkine patent portfolio for partnering
It adds value because Pfizer is running an array of Glioblastoma trials and they co-funded the Complutense pre-clinical study AND because the midkine antibody works in conjunction with other chemo.
My suggestion is the Pfizer will take this forward because of the results thus far.
- Forums
- ASX - By Stock
- AN1
- Ann: Patent for Improved Midkine Antibody Allowed in Europe
Ann: Patent for Improved Midkine Antibody Allowed in Europe, page-2
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.8¢ | 0.8¢ | 0.8¢ | $8.397K | 1.053M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1111500 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 36716 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1111500 | 0.007 |
4 | 606527 | 0.006 |
1 | 300000 | 0.005 |
2 | 525000 | 0.004 |
1 | 600000 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.008 | 36716 | 1 |
0.009 | 340000 | 1 |
0.010 | 157763 | 1 |
0.011 | 100000 | 1 |
0.012 | 100000 | 1 |
Last trade - 15.46pm 18/07/2024 (20 minute delay) ? |
Featured News
AN1 (ASX) Chart |